The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis
ConclusionsOur results suggest that multitarget therapy using mizoribine opposed to MMF is highly safe and effective through 12 months. The therapy may enable faster dose reduction of concomitant glucocorticoids.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Cytomegalovirus | Lupus | Nephritis | Pneumonia | Prednisolone | Prograf | Proteinuria | Respiratory Medicine | Study | Tacrolimus | Urology & Nephrology